JP2020523348A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523348A5
JP2020523348A5 JP2019568372A JP2019568372A JP2020523348A5 JP 2020523348 A5 JP2020523348 A5 JP 2020523348A5 JP 2019568372 A JP2019568372 A JP 2019568372A JP 2019568372 A JP2019568372 A JP 2019568372A JP 2020523348 A5 JP2020523348 A5 JP 2020523348A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
cancer
salt according
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568372A
Other languages
English (en)
Japanese (ja)
Other versions
JP6979595B2 (ja
JP2020523348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037221 external-priority patent/WO2018231910A1/en
Publication of JP2020523348A publication Critical patent/JP2020523348A/ja
Publication of JP2020523348A5 publication Critical patent/JP2020523348A5/ja
Application granted granted Critical
Publication of JP6979595B2 publication Critical patent/JP6979595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568372A 2017-06-13 2018-06-13 プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 Active JP6979595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
US62/518,855 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2020523348A JP2020523348A (ja) 2020-08-06
JP2020523348A5 true JP2020523348A5 (https=) 2021-07-26
JP6979595B2 JP6979595B2 (ja) 2021-12-15

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019568372A Active JP6979595B2 (ja) 2017-06-13 2018-06-13 プロテインキナーゼ阻害剤としてのアミノチアゾール化合物

Country Status (13)

Country Link
US (1) US10300061B2 (https=)
EP (1) EP3638237B1 (https=)
JP (1) JP6979595B2 (https=)
KR (1) KR102372288B1 (https=)
CN (1) CN110831596B (https=)
AU (1) AU2018284249B2 (https=)
CA (1) CA3064081C (https=)
ES (1) ES2949616T3 (https=)
MX (1) MX393992B (https=)
MY (1) MY201291A (https=)
TW (1) TWI667236B (https=)
WO (1) WO2018231910A1 (https=)
ZA (1) ZA202000107B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
CN115279754A (zh) * 2019-11-14 2022-11-01 A2A制药有限公司 靶向tacc3的异恶唑衍生物作为抗癌剂
US20230131830A1 (en) * 2020-03-06 2023-04-27 National Health Research Institutes Pyrimidine compounds and their pharmaceutical uses
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2503715A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
WO2006106437A2 (en) 2005-04-04 2006-10-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
EP1893607A4 (en) * 2005-06-09 2010-07-21 Merck Sharp & Dohme CHECKPOINT KINASE INHIBITORS
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
CN103717591B (zh) 2011-07-27 2016-08-24 Ab科学有限公司 作为选择性蛋白激酶(c-kit)抑制剂的噁唑和噻唑衍生物
WO2013143466A1 (zh) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Similar Documents

Publication Publication Date Title
JP2020523348A5 (https=)
JP2019511564A5 (https=)
JP6495868B2 (ja) キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
CN105163584B (zh) 用于治疗癌症的化合物
ES2779152T3 (es) Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
TWI594986B (zh) Antineoplastic agent effect enhancer
WO2020130125A1 (ja) 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
ES2576497T3 (es) Compuesto de piperidina novedoso o sal del mismo
JP2019535746A5 (https=)
JP2020503299A5 (https=)
CA2519898A1 (en) Oral administration of cyclic protein tyrosine kinase inhibitors
RU2016130932A (ru) Производные хинолона как ингибиторы рецептора фактора роста фибробластов
WO2018147275A1 (ja) 腫瘍治療用医薬組成物
JP2020536971A5 (https=)
JP2005508953A5 (https=)
JP6883913B2 (ja) ヒストンデメチラーゼ阻害剤
RU2016137356A (ru) Соединение нафтиламида, способ его получения и применение
JP2020534300A5 (https=)
RU2010106241A (ru) Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr
JP2023542065A5 (https=)
CA3130471A1 (en) Pan-raf kinase inhibitor and use thereof
TWI258481B (en) Hexacyclic compounds
CN117865886A (zh) 一种n-(喹啉-8-基)喹啉-8-磺酰胺类化合物及其应用
RU2019137573A (ru) Аминотиазольные соединения в качестве ингибиторов протенкиназ